EquitySectoral/ ThematicDirectGrowthVery High

PGIM India Healthcare Fund

Q: What is the NAV of PGIM India Healthcare Fund?

As of 05 Oct 2026, the NAV of PGIM India Healthcare Fund is ₹12.11 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

Q: What returns has PGIM India Healthcare Fund delivered?

PGIM India Healthcare Fund has returned +24.20% over 1 year and +11.25% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

Q: What is the expense ratio of PGIM India Healthcare Fund?

PGIM India Healthcare Fund charges an expense ratio of 1.00% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

Q: What are the top holdings of PGIM India Healthcare Fund?

PGIM India Healthcare Fund's largest holdings are Divi's Laboratories Ltd. (10.8%), Sun Pharmaceutical Industries Ltd. (10.7%), Torrent Pharmaceuticals Ltd. (8.9%), Max Healthcare Institute Ltd. (5.0%) and Ajanta Pharma Ltd. (4.8%). Holdings are disclosed monthly and change over time.

Q: How risky is PGIM India Healthcare Fund?

PGIM India Healthcare Fund is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 13.1% and its worst peak-to-trough fall in our sample was -14.5%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

Q: What is the benchmark of PGIM India Healthcare Fund?

PGIM India Healthcare Fund is benchmarked against the BSE Healthcare TRI. Its alpha and beta on this page are measured against that index.

Q: Who manages PGIM India Healthcare Fund?

PGIM India Healthcare Fund is managed by Puneet Pal, Vivek Sharma, Anandha Padmanabhan Anjeneyan and Utsav Mehta at PGIM India.

Q: How is PGIM India Healthcare Fund taxed?

PGIM India Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.

PGIM India Mutual Fund · Best Sectoral & Thematic Mutual Funds

NAV

₹12.11

-1.06% 1D

as of 05 Oct 2026

This is the Direct plan of PGIM India Healthcare Fund — bought from the fund house, with no distributor commission in its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.

Compare SIP calculator

Performance

+22.82%absolute

52-week rangePrev NAV ₹12.24

Latest ₹12.11

Low ₹9.4281st percentile of its 52-week rangeHigh ₹12.75

Scorecard

★★★★★5/5 vs 229 of 255 Sectoral/ Thematic peers1Y

Performance 60%
Risk 15%
Cost 10%
Downside 15%

How this is computed

Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. The stars weight the same ground 60/15/10/15 (performance/risk/cost/downside) across every fund in the peer group. Ranked within Sectoral/ Thematic (same plan and option). Based on a 1-year record — this fund is too young for a 3-year CAGR, so its performance is ranked on 1Y against the same peers. 229 of the 255 Sectoral/ Thematic funds in this cohort carry the full record the stars need, so they are the ones ranked against.

Performance—

Not enough Sectoral/ Thematic peers to rank yet

RiskLow

Volatility 13.1% vs 15.7% category avg

CostLow

1.0% expense vs 1.3% category avg

Consistency—

Not enough history for a rolling 3Y view

Strengths & concerns

Generated from this fund's own numbers against its sub-category — each point names the figure behind it.

Strengths

Ahead of the Sectoral/ Thematic average on 1M/3M/6M/1Y — 1Y by 20.90pp
Ranks #7 of 229 on 1-year return in its Sectoral/ Thematic cohort
Less volatile than its Sectoral/ Thematic peers (13.1% vs 15.7%)
Low expense ratio (1.00%) vs the Sectoral/ Thematic average of 1.27%

Concerns

No significant concerns identified.

Key Metrics

Annual fee charged by the fund, already deducted from NAV

1.00%

Category 1.27%▼0.27%

Portfolio-weighted harmonic mean P/E across the fund's equity holdings

49.56

Category 28.58▲20.98

Excess return per unit of total volatility (rf = 6.5%)

—

Category 0.45

Scheme Info

Definitions

Plan

Direct · Growth

Period before units can be redeemed — 3 years for ELSS, none for most open-ended funds

None

- For each purchase of units through Lumpsum / switch‐in / Systematic Investment Plan (SIP) and Systematic Transfer Plan (STP), exit load will be as follows: • For Exits within 90 days from date of allotment of units : 0.50%. • For Exits beyond 90 days from date of allotment of units : NIL The entire exit load (net of Goods and Services tax), charged, if any, shall be credited to the Scheme.

Up to 0.50%

tiered — see the full terms

Statutory levy on every mutual-fund purchase since 1 Jul 2020 (SEBI / Govt of India) — the same for every scheme

0.005%

SIP Inv.

Allowed

Smallest recurring SIP instalment the scheme accepts

₹1,000

Smallest one-time (lumpsum) investment the scheme accepts

₹5,000

BSE Healthcare TRI

Start of our NAV history for this plan. Direct plans begin 1 Jan 2013, so this is the plan's inception — not necessarily the scheme's original launch date.

11 Dec 2024

Period returns (<1Y, absolute — not annualized)

Definitions

Absolute return over the last 1 month (not annualized)

-2.89%

Absolute return over the last 3 months (not annualized)

+3.15%

Absolute return over the last 6 months (not annualized)

+25.36%

Absolute return since 1 Jan of this year (not annualized)

+20.86%

Annualized returns (≥1Y — CAGR)

Definitions

1-year point-to-point return, annualized (CAGR)

+24.20%

3-year annualized return (CAGR)

—

5-year annualized return (CAGR)

—

10-year annualized return (CAGR)

—

Annualized return (CAGR) since the first NAV we hold for this plan — the Inception date under Key metrics. AMFI's history starts in April 2006, so an older scheme is measured from there.

+11.25%

Advanced metrics — risk and benchmark ratios

Risk (trailing 3Y)

Definitions

Annualized standard deviation of daily returns

13.14%

Excess return per unit of total volatility (rf = 6.5%)

—

Excess return per unit of downside deviation — upside swings aren't penalized (rf = 6.5%)

—

Largest peak-to-trough decline over full history

-14.45%

Benchmark ratios (vs Nifty 500 TRI · 36 monthly returns)

Definitions

Jensen's alpha (annualized): return above what CAPM predicts for the fund's beta vs Nifty 500 TRI

—

Sensitivity to Nifty 500 TRI moves; 1 = moves with the index

—

How much of the fund's movement Nifty 500 TRI explains

—

Excess return per unit of beta (market risk)

—

Active return over the benchmark per unit of tracking error

—

Annualized std dev of fund-minus-benchmark returns

—

Fund's share of benchmark gains in up months (100 = matches index)

—

Fund's share of benchmark losses in down months (lower is better)

—

Computed vs the Nifty 500 TRI over the last 36 complete months — the closest match to this fund's mandate. TRI means dividends reinvested, as they are in the fund's own NAV; ₹ means a US index converted at each day's USD/INR, since the fund is priced in rupees. Needs ~3 years of history; a low R² means the fund tracks the index loosely.

Fund vs category average (Sectoral/ Thematic)

Period	Fund	Category avg.	Diff
1M abs	-2.89%	-4.48%	+1.59%
3M abs	+3.15%	-2.35%	+5.50%
6M abs	+25.36%	+12.01%	+13.35%
1Y CAGR	+24.20%	+3.30%	+20.90%
3Y CAGR	—	+13.80%	—
5Y CAGR	—	+12.04%	—

Category average across peers in Sectoral/ Thematic (up to 255 funds with data), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Category rank

Vs 255 peers in Sectoral/ Thematic

1Y return

+24.20%

Beats 97.4% · rank #7

3Y return

—

5Y return

—

Sharpe

—

Sortino

—

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Monthly investment (₹)

Period

Invested

₹1.20L

Current value

₹1.35L

Absolute

+12.29%

XIRR

+27.98%

Value vs. invested

ValueInvested

12 monthly installments of ₹10,000 into PGIM India Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.

Calendar-year returns

What the fund actually returned in each year, not the smoothed average.

Year	Fund	Nifty 500 TRI	Diff
2026part	+20.86%	-7.18%	+28.04%
2025	-0.99%	+7.94%	-8.93%
2024part	+1.40%	—	—

January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.

History points

447

Expense ratio

1.00%

AUM

₹94.43Cr

Portfolio turnover

33%

Exit load

P/E ratio

49.6

P/B ratio

9.8

Avg market cap

₹1,30,514Cr

P/E & P/B are portfolio-weighted harmonic means across 26 of 31 equity holdings (83% of the portfolio); loss-making companies are excluded.

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)

20%

Held under 1 year

Flat, on the whole gain

Long-term (LTCG)

12.5%

Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Peer comparison · Sectoral/ Thematic

Compare all


PGIM India Healthcare FundThis fund PGIM India · Direct · Growth	★★★★★ 1Y	+24.20%	—	—	49.56	1.00%	₹94.43Cr
Nippon India Taiwan Equity Fund Nippon India · Direct · Growth	★★★★☆	+128.11%	+63.78%	—	—	1.06%	₹1,110Cr
HDFC Defence Fund HDFC · Direct · Growth	★★★★☆	+20.18%	+36.05%	—	57.59	0.89%	₹9,371Cr
HDFC Pharma and Healthcare Fund HDFC · Direct · Growth	★★★★★	+25.57%	+29.81%	—	44.12	1.03%	₹2,282Cr
Franklin Asian Equity Fund Franklin Templeton · Direct · Growth	★★★☆☆	+32.46%	+25.00%	+9.83%	26.07	1.21%	₹720.84Cr
Nippon India Japan Equity Fund Nippon India · Direct · Growth	★★★☆☆	+30.50%	+24.42%	+12.14%	—	1.37%	₹330.20Cr

Market-cap allocation · AMFI bands, Jul 2026

Equity holdings by company size — 100% of the equity sleeve priced.

Large cap36.9%
Mid cap37.6%
Small cap25.5%

Asset allocation

As on 31 Aug 2026 · AMC disclosure

Equity94.58%
Cash & Equivalents5.42%

which companies this fund invests in

As on 31 Aug 2026 · AMC disclosure

Divi's Laboratories Ltd.

10.85%

Sun Pharmaceutical Industries Ltd.

10.74%

Torrent Pharmaceuticals Ltd.

8.86%

Max Healthcare Institute Ltd.

4.96%

Ajanta Pharma Ltd.

4.83%

Manipal Health Enterprises Ltd.

4.12%

Mankind Pharma Ltd.

4.07%

Rubicon Research Ltd.

4.01%

Dr. Lal Path Labs Ltd.

3.93%

Neuland Laboratories Ltd.

3.26%

Holds the same stocks as (by portfolio overlap, not by category)

Compare the top 3 →

Fund	Overlap	Rating	TER	3Y
HDFC Pharma and Healthcare Fund HDFC · Sectoral/ Thematic	55.2%	★★★★★	1.03%	+29.81%
WhiteOak Capital Pharma and Healthcare Fund WhiteOak Capital · Sectoral/ Thematic	55.1%	★★★★★	1.06%	—
Kotak Healthcare Fund Kotak Mahindra · Sectoral/ Thematic	54.0%	★★★★★	1.04%	—
SBI Healthcare Opportunities Fund SBI · Sectoral/ Thematic	52.1%	★★★★★	1.01%	+22.92%
Mirae Asset Healthcare Fund Mirae Asset · Sectoral/ Thematic	51.8%	★★★★★	0.62%	+22.23%
ITI Pharma and Healthcare Fund ITI · Sectoral/ Thematic	51.3%	★★★★★	0.89%	+19.16%
Aditya Birla Sun Life Pharma and Healthcare Fund Aditya Birla Sun Life · Sectoral/ Thematic	49.4%	★★★★★	1.05%	+20.45%
LIC MF Healthcare Fund LIC · Sectoral/ Thematic	48.3%	★★★★★	1.38%	+21.38%

Overlap is the share of each fund's equity book invested in the same stocks, by weight, across the Direct-plan universe — so a fund that is only part equity is labelled as such. ! marks a pair holding more in common than nine pairs in ten of its type, where that type has a measured distribution.

🚩Holdings under NSE surveillance (ASM)

1 holding — 4.01% of the portfolio — sit in stocks NSE currently lists under its Additional Surveillance Measure. ASM is an exchange response to unusual price or volume activity (higher margins, and trade-for-trade settlement at stage II), not a view on the company or on this fund.

Rubicon Research LimitedLong-term · Stage I4.01%

Source: NSE ASM list, matched to holdings by company name — a holding whose name differs from NSE's spelling may not be matched. BSE's separate list is not covered.

Worst falls, and the wait to get back

How far this fund has dropped from a high, and how long it took to reclaim it.

-14.4%07 Jan 2025 → 28 Feb 2025
Fell over 2 months, back to the old high on 15 Jul 2025 — 5 months under water after the low.
-8.7%30 Jul 2025 → 29 Jan 2026
Fell over 6 months, back to the old high on 26 Feb 2026 — 28 days under water after the low.
-6.8%26 Feb 2026 → 02 Apr 2026
Fell over 35 days, back to the old high on 27 Apr 2026 — 25 days under water after the low.

Measured on this fund’s own NAV history, peak to trough to the day it regained the peak. Falls shallower than 5% are left out. A recovery date is when the NAV got back, not when any particular investor did — that depends on when they bought.

Fund size over time

Quarterly average AUM · AMFI

₹94.43Cr

April - June 2026

+4%

since January - March 2026

−₹6.39Cr

est. net flow, last quarter

At or near its largest, ₹94.43Cr in April - June 2026. Size matters most where the mandate is narrow — a large small-cap or a very large flexi-cap book is harder to move without moving the price.

Net flow is an estimate: AMFI publishes a quarterly average AUM, not a closing balance, and it covers every plan and option of this scheme together, so it is a read on direction and rough size rather than a cash-flow statement.

AMC Profile

PGIM India Mutual Fund is the Indian arm of PGIM, the global asset management business of the US insurer Prudential Financial. It was formerly DHFL Pramerica Mutual Fund; PGIM bought out DHFL's stake in 2019 and renamed the house.

Launched

12 May 2010

Total AUM

₹27,859Cr+4.6% QoQ

Avg AUM · July - September 2026

Website

pgimindia.com/mutual-funds

Fund Managers

PPPuneet PalStart date not disclosed

Education

MBA (Finance) from Symbiosis Institute of Business Management, Pune Category of the Scheme Arbitrage Fund Balanced Advantage Fund Equity Savings Fund

Experience

More than 25 years of PGIM experience in the Debt markets Fund, PGIM India Flexi within the Mutual Fund space. Below are details on his past stints: • December 01, 2021 onwards – Head – Fixed Income - PGIM India Asset Fund, PGIM India Equity Management Private Savings Limited. • December 13, 2017 to November 30, 2021 Deputy Head - Fixed PGIM Income - PGIM India Asset Management Private Limited. • February 2012 to December 12, 2017 - Head - Fixed Income - BNP Paribas Asset Management India Pvt. Ltd. • July 2008 to February 2012 - Sr. Vice President & Fund Manager - UTI Asset Management Company Ltd. • August 2006 to July 2008 - Fund Manager - Tata Asset Management Ltd. • April 2004 to August 2006 - Asst. Fund Manager - UTI Asset Management Company Ltd. • June 2001 to March 2004 - Dealer - UTI Asset Management Company Ltd.

Funds managed (21)

All schemes Puneet Pal runs →

VSVivek SharmaStart date not disclosed

Education

PGDM - Finance

Experience

Collectively over 15 years of experience in Equity market, research and fund Management : • April 09, 2024 onwards - PGIM India Asset Management Pvt Ltd. - Fund Manager – Equity • September 01, 2023 to March 20, 2024 - Edelweiss Asset Management Limited - Fund Manager – Equity • March 09, 2017 to August 18, 2023 - PGIM India Asset Management Private Limited - Fund Manager – Equity • October 01, 2010 to March 06, 2017 - ICICI Securities Ltd - Research Analyst

Funds managed (13)

All schemes Vivek Sharma runs →

AAAnandha Padmanabhan AnjeneyanStart date not disclosed

Education

B Com, ACA, CFA, FRM

Experience

Collectively over 17 years of experience in Indian financial markets, primarily in equity research: • June 1, 2021 onwards – PGIM India Asset Management Pvt. Ltd. – Equity Analyst and Assistant Fund Manager – Equity • January 2020 to May 31, 2021 – PGIM India Asset Management Pvt. Ltd. – Equity Analyst and Dedicated Fund Manager – Overseas Investments • March 2019 to January 2020 – PGIM India Asset Management Pvt. Ltd. – Equity Analyst • May 2018 to March 2019 – Equity Analyst – Renaissance Investment Managers Private Ltd. • August 2010 to May 2018 – Equity Analyst – Canara Robeco Asset Management Company Ltd. • September 2009 to August 2010 – Fixed Income Dealer- Canara Robeco Asset Management Company Ltd.

Funds managed (12)

All schemes Anandha Padmanabhan Anjeneyan runs →

UMUtsav MehtaStart date not disclosed

Education

B.Com., CFA : B.Com, ACA, CFA, FRM : M.M.S

Experience

Over 14 years of experience in Equity market, research and fund management : • October 23, 2023 onwards - PGIM India Asset Management Pvt Ltd. - Vice President - Fund Manager - Equity. • September 2018 to October 2023 - Edelweiss Asset Management Ltd - VP, Alternatives. • June 2014 to September 2018 - Ambit Capital - Sector Analyst - Institutional Equities. • January 2014 to May 2014 - MF Advisors LLP - Analyst – Investments. • November 2012 - December 2013 - Ambit Capital - Associate – Investment Research

Funds managed (5)

All schemes Utsav Mehta runs →

Fund manager, benchmark and dealing terms from this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.

Explore from here

Fund managers

Puneet Pal Vivek Sharma Anandha Padmanabhan Anjeneyan Utsav Mehta

Top holdings

Divi's Laboratories Ltd.Sun Pharmaceutical Industries Ltd.Torrent Pharmaceuticals Ltd.Max Healthcare Institute Ltd.Ajanta Pharma Ltd.Manipal Health Enterprises Ltd.Mankind Pharma Ltd.Rubicon Research Ltd.Dr. Lal Path Labs Ltd.Neuland Laboratories Ltd.Krishna Inst of Medical Sciences Ltd.Navin Fluorine International Ltd.

PGIM India in the news

Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.

Run SIP calculator Add to compare

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Sectoral & Thematic funds

Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.

From the blog

Pharma and healthcare funds: all 17 are up over the year
02 Oct 2026
All 17 pharma and healthcare funds with a one-year record gained in the year to 1 October 2026; the median made 17.50%. Best, worst, 3 and 5-year returns.

Frequently asked questions

What is the NAV of PGIM India Healthcare Fund?

As of 05 Oct 2026, the NAV of PGIM India Healthcare Fund is ₹12.11 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has PGIM India Healthcare Fund delivered?

PGIM India Healthcare Fund has returned +24.20% over 1 year and +11.25% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of PGIM India Healthcare Fund?

PGIM India Healthcare Fund charges an expense ratio of 1.00% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

What are the top holdings of PGIM India Healthcare Fund?

PGIM India Healthcare Fund's largest holdings are Divi's Laboratories Ltd. (10.8%), Sun Pharmaceutical Industries Ltd. (10.7%), Torrent Pharmaceuticals Ltd. (8.9%), Max Healthcare Institute Ltd. (5.0%) and Ajanta Pharma Ltd. (4.8%). Holdings are disclosed monthly and change over time.

How risky is PGIM India Healthcare Fund?

PGIM India Healthcare Fund is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 13.1% and its worst peak-to-trough fall in our sample was -14.5%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What is the benchmark of PGIM India Healthcare Fund?

PGIM India Healthcare Fund is benchmarked against the BSE Healthcare TRI. Its alpha and beta on this page are measured against that index.

Who manages PGIM India Healthcare Fund?

PGIM India Healthcare Fund is managed by Puneet Pal, Vivek Sharma, Anandha Padmanabhan Anjeneyan and Utsav Mehta at PGIM India.

How is PGIM India Healthcare Fund taxed?

PGIM India Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.

PGIM India Healthcare Fund

Performance

Scorecard

Strengths & concerns

Strengths

Concerns

Key Metrics

Scheme Info

Period returns (<1Y, absolute — not annualized)

Annualized returns (≥1Y — CAGR)

Fund vs category average (Sectoral/ Thematic)

Category rank

Backtest this fund

Calendar-year returns

Taxation

Peer comparison · Sectoral/ Thematic

Market-cap allocation · AMFI bands, Jul 2026

Asset allocation

Holds the same stocks as (by portfolio overlap, not by category)

🚩Holdings under NSE surveillance (ASM)

Fund size over time

AMC Profile

Fund Managers

Explore from here

PGIM India in the news

About Sectoral & Thematic funds

From the blog

Pharma and healthcare funds: all 17 are up over the year

Frequently asked questions

Peer comparison · Sectoral/ Thematic

Market-cap allocation · AMFI bands, Jul 2026

Holds the same stocks as (by portfolio overlap, not by category)

🚩Holdings under NSE surveillance (ASM)